Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent underwhelming data for CagriSema, but the Danish pharma has given […]
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent underwhelming data for CagriSema, but the Danish pharma has given […]